Merck's Niacin-Laropiprant Cholesterol Trial Terminated Before Completion
A phase 3 trial adding ERN/LRPT to statin therapy for dyslipidemia was terminated early, raising questions about the drug's clinical future.
Summary
This phase 3 randomized controlled trial tested whether adding extended-release niacin combined with laropiprant — a drug designed to reduce niacin-induced flushing — could further lower LDL cholesterol in patients already on statin or ezetimibe therapy. Participants had primary hypercholesterolemia or mixed dyslipidemia. The hypothesis was that 2 grams daily of the combination would outperform placebo at 12 weeks. Sponsored by Merck, the trial was conducted across multiple centers but was ultimately terminated before completion. The early termination likely reflects broader concerns about the niacin/laropiprant combination, which was eventually withdrawn from global markets after the large HPS2-THRIVE trial showed no cardiovascular benefit and increased serious adverse events when niacin/laropiprant was added to statin therapy.
Detailed Summary
Managing cholesterol remains central to cardiovascular risk reduction, and for years niacin was considered a promising add-on therapy to statins given its ability to raise HDL and lower triglycerides alongside LDL. However, patient adherence was hampered by uncomfortable flushing. Laropiprant, a prostaglandin D2 receptor antagonist, was developed specifically to block niacin-induced flushing and improve tolerability, leading to the combination product ERN/LRPT.
This multicenter, randomized, double-blind, placebo-controlled phase 3 trial enrolled patients with primary hypercholesterolemia or mixed dyslipidemia who were already receiving ongoing lipid-modifying therapy — including simvastatin, atorvastatin, rosuvastatin, ezetimibe/simvastatin FDC, or any statin plus ezetimibe. The primary hypothesis was that ERN/LRPT at 2 g daily would be superior to placebo in reducing LDL-C after 12 weeks of add-on treatment.
The trial was terminated before completion. No results from this specific study are publicly available, and the reasons for termination are not detailed in the registry entry. The termination aligns temporally with the broader fate of laropiprant-containing products globally. The pivotal HPS2-THRIVE trial — a massive outcome study involving over 25,000 patients — ultimately found that adding extended-release niacin/laropiprant to statin therapy did not reduce major cardiovascular events and was associated with a significant increase in serious adverse effects, including infections, bleeding, and new-onset diabetes. As a consequence, the European Medicines Agency suspended ERN/LRPT, and Merck withdrew the product worldwide.
For clinicians, this trial's termination is a cautionary data point: lipid-modifying add-ons that improve biomarkers do not automatically translate into clinical benefit. The niacin/laropiprant story underscores the importance of hard cardiovascular outcomes over surrogate endpoints like LDL-C reduction alone.
Caveats are significant. This summary is based only on the registry abstract, and no efficacy or safety data from this specific trial are available. The terminated status means the 12-week LDL-C endpoint was never formally reported.
Key Findings
- Trial was terminated before completion, preventing reporting of primary LDL-C reduction endpoint at 12 weeks.
- ERN/LRPT 2g daily was tested as an add-on to multiple statin and ezetimibe regimens in dyslipidemia patients.
- Termination aligns with global withdrawal of niacin/laropiprant after HPS2-THRIVE showed no cardiovascular benefit.
- Biomarker improvement (LDL-C lowering) does not guarantee clinical cardiovascular outcome benefit.
- Laropiprant was intended to solve niacin flushing but could not rescue the combination's risk-benefit profile.
Methodology
Phase 3, multicenter, randomized, double-blind, placebo-controlled design. Participants with primary hypercholesterolemia or mixed dyslipidemia were randomized to ERN/LRPT 2g daily or placebo added to ongoing lipid-modifying therapy. Primary endpoint was LDL-C change at 12 weeks; the trial was terminated before completion.
Study Limitations
This summary is based on the clinical trial registry abstract only, as no results data or full publication are publicly available. The trial was terminated prior to completion, meaning no efficacy or safety findings were reported. Reasons for termination are not specified in the registry entry, though external context from HPS2-THRIVE strongly informs interpretation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.